Join us for the PolTREG Q1 2025 financial results webinar!
We are pleased to invite you to our upcoming webinar, which will present the financial results for Q1 2025 and PolTREG’s development plans.
Join us on Friday, May 16 at 1:00 PM CEST, where you will hear directly from our company’s management:
• Piotr Trzonkowski, Co-founder and CEO
• Mariusz Jablonski, Member of the Management Board
• Dan Shelly, Chief Business Development Officer
• Marcin Kądziela, CFO
The webinar will be conducted in Polish and partially in English.
Register for free
2025-05-14
PolTREG Q1 2025 financial results webinar
See other news
2025-08-04
PolTREG Doses First Patient in Phase II Trial for Pre-Symptomatic Type 1 Diabetes with PTG-007
2025-07-31
PolTREG Secures Positive FDA Opinion, Paving the Way for a Registrational Pre-Symptomatic Type 1 Diabetes Trial
2025-06-13
PolTREG Establishes U.S. Subsidiary Immuthera to Advance International Development Strategy
2025-04-23
PolTREG accelerates the development of next-generation antigen-specific Tregtherapy for Type 1 Diabetes